161712-76-1

Basic information

• Product Name: 3-(3,4-difluorophenyl)propanoyl chloride
• Synonyms: 3-(3,4-difluorophenyl)propanoyl chloride
• CAS NO: 161712-76-1
• Molecular Weight: 204.604
• Mol File: 161712-76-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-(3,4-difluorophenyl)propanoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,4-difluorophenyl)propanoyl chloride(161712-76-1)
• EPA Substance Registry System: 3-(3,4-difluorophenyl)propanoyl chloride(161712-76-1)

Safety Data

• Hazardous Substances Data: 161712-76-1(Hazardous Substances Data)

Upstream product

• 161712-75-0 3-(3,4-difluorophenyl)-propanoic acid 
• 34036-07-2 3,4 difluorobenzaldehyde 
• 803687-25-4 ethyl 3-(3,4-difluorophenyl)propanoate 
• 375368-92-6 ethyl 3-(3,4-difluorophenyl)acrylate 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 815618-48-5 4-(R)-benzyl-3-[3-(3,4-difluorophenyl)propionyl]oxazolidine-2-one 
• 161712-77-2 5,6-difluoroindan-1-one 
• 881190-18-7 6,7-difluoroindanone 

Relevant articles and documents

B-973, a Novel α7 nAChR Ago-PAM: Racemic and Asymmetric Synthesis, Electrophysiological Studies, and in Vivo Evaluation

We report here the total synthesis of B-973 (five steps), a recently identified α7 nAChR ago-PAM, its enantiomeric resolution, and its electrophysiological characterization in Xenopus oocytes to identify (-)-B-973B as the bioactive enantiomer. The asymmetric synthesis of B-973B was accomplished in 99% ee, and X-ray crystallography studies revealed its absolute "S" stereochemistry. B-973B was effective in attenuating pain behavior and decreasing paw edema (formalin test), and its analgesic effects were mediated through α7 nAChR.

Design, synthesis, and pharmacological evaluation of fused β-homophenylalanine derivatives as potent DPP-4 inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors are accepted as a favorable class of agents for the treatment of type 2 diabetes. Herein, a series of fused β-homophenylalanine derivatives as novel DPP-4 inhibitors were designed, synthesized, and evaluated for their inhibitory activities against DPP-4. Most of them displayed excellent DPP-4 inhibitory activities and good selectivity. Among them, 9aa, 18a, and 18m also showed good efficacy in an oral glucose tolerance test (OGTT) in ICR mice. Moreover, when dosed 8 h prior to glucose challenge, 18m showed significantly greater potency than sitagliptin. It thus provides potential candidates for the further development into potent drugs targeting DPP-4.

NOVEL HETEROCYCLE COMPOUNDS

The present invention relates to novel compounds which are antagonist or inverse agonists at an opioid receptor. Such compounds are useful in the treatment of obesity and related diseases and/or conditions in mammals, particularly humans. Methods of making and using such compounds are also disclosed.